<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036733</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00196809</org_study_id>
    <nct_id>NCT05036733</nct_id>
  </id_info>
  <brief_title>Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma</brief_title>
  <official_title>Effects of IL-4R-alpha Inhibition (Dupixent) Inhibition On The Respiratory Microbiome And Immunologic Correlates In Patients With Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to understand biological responses related to dupilumab&#xD;
      treatment among severe asthma patients.&#xD;
&#xD;
      Not all asthma is the same, and characteristics of asthma vary from person to person. The&#xD;
      study will investigate whether the study drug can help to improve the health of participants&#xD;
      lungs, boost immune response, as well as improve quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in alpha-diversity of respiratory microbiota</measure>
    <time_frame>Baseline (before dupilumab), 1 month</time_frame>
    <description>This will be profiled from induced sputum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in alpha-diversity of respiratory microbiota</measure>
    <time_frame>Baseline (before dupilumab), 4 month</time_frame>
    <description>This will be profiled from induced sputum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in alpha-diversity of respiratory microbiota</measure>
    <time_frame>1 month, 4 months</time_frame>
    <description>This will be profiled from induced sputum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beta-diversity of respiratory microbiota</measure>
    <time_frame>Baseline (before dupilumab), 1 month</time_frame>
    <description>This will be profiled from induced sputum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beta-diversity of respiratory microbiota</measure>
    <time_frame>Baseline (before dupilumab), 4 month</time_frame>
    <description>This will be profiled from induced sputum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beta-diversity of respiratory microbiota</measure>
    <time_frame>1 month, 4 months</time_frame>
    <description>This will be profiled from induced sputum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in relative abundances of microbiota members</measure>
    <time_frame>Baseline (before dupilumab), 1 month</time_frame>
    <description>This will be profiled from induced sputum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in relative abundances of microbiota members</measure>
    <time_frame>Baseline (before dupilumab), 4 month</time_frame>
    <description>This will be profiled from induced sputum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in relative abundances of microbiota members</measure>
    <time_frame>1 month, 4 months</time_frame>
    <description>This will be profiled from induced sputum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in respiratory bacterial burden</measure>
    <time_frame>Baseline (before dupilumab), 1 month</time_frame>
    <description>This will be profiled from induced sputum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in respiratory bacterial burden</measure>
    <time_frame>Baseline (before dupilumab), 4 month</time_frame>
    <description>This will be profiled from induced sputum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in respiratory bacterial burden</measure>
    <time_frame>1 month, 4 months</time_frame>
    <description>This will be profiled from induced sputum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in alpha-diversity of stool microbiota</measure>
    <time_frame>Baseline (before dupilumab), 1 month</time_frame>
    <description>This will be based on stool samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in alpha-diversity of stool microbiota</measure>
    <time_frame>Baseline (before dupilumab), 4 month</time_frame>
    <description>This will be based on stool samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in alpha-diversity of stool microbiota</measure>
    <time_frame>1 month, 4 months</time_frame>
    <description>This will be based on stool samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beta-diversity of stool microbiota</measure>
    <time_frame>Baseline (before dupilumab), 1 month</time_frame>
    <description>This will be based on stool samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beta-diversity of stool microbiota</measure>
    <time_frame>Baseline (before dupilumab), 4 month</time_frame>
    <description>This will be based on stool samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beta-diversity of stool microbiota</measure>
    <time_frame>1 month, 4 months</time_frame>
    <description>This will be based on stool samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume ( FEV1) / forced vital capacity (FVC) ratio</measure>
    <time_frame>up to 4 months</time_frame>
    <description>This will be based on Spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume (FEV1)</measure>
    <time_frame>up to 4 months</time_frame>
    <description>This will be based on Spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fractional exhaled nitric oxide (FeNO)</measure>
    <time_frame>Baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Test (ACT)</measure>
    <time_frame>up to 4 months</time_frame>
    <description>This is a self-administered 5 item questionnaire. The ACT score is the sum of the values for all 5 items. The scores range from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. An ACT score &gt;19 indicates well-controlled asthma; the minimal clinically important difference in score is 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini Asthma Quality of Life Questionnaire Score (mAQLQ)</measure>
    <time_frame>up to 4 months</time_frame>
    <description>This is a patient self-administered questionnaire with 15 questions covering 4 domains: Symptoms (5 questions), Activity Limitations (4 questions), Emotional Function (3 questions), and Environmental Stimuli (3 questions). Scores range from 0-6 (lower is worse). The mini AQLQ score is calculated as the average of domain items. The minimum clinically important difference is 0.5.&#xD;
Overall score (average of 15 questions): add up responses to all questions, and divide by 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sino-nasal outcome test (SNOT-22)</measure>
    <time_frame>up to 4 months</time_frame>
    <description>This is a 22 item questionnaire. Each item is rated as follows: 0=no problem, 1=very mild problem, 2=mild or slight problem, 3=moderate problem, 4=severe problem, 5=problem as bad as it can be. The score ranges between 0 and 110. A higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prescribed maintenance corticosteroid use (inhaled or oral), between baseline and 4 months.</measure>
    <time_frame>Baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of asthma exacerbations requiring at least 3 days of oral corticosteroids</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.&#xD;
Additionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.</description>
    <arm_group_label>Dupilumab</arm_group_label>
    <other_name>Dupixent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Physician-diagnosed/managed severe asthma patients that are clinically eligible for&#xD;
             dupilumab&#xD;
&#xD;
          -  Current treatment with a medium-to-high-dose inhaled glucocorticoid (fluticasone&#xD;
             propionate at a total daily dose of greater or equal (≥) 440 μg or equipotent&#xD;
             equivalent) plus up to at least one additional controller (e.g., a long-acting&#xD;
             β2-agonist or leukotriene receptor antagonist)&#xD;
&#xD;
          -  Eosinophilic asthma phenotype (blood eosinophil level &gt;300) or asthma requiring daily&#xD;
             oral corticosteroids&#xD;
&#xD;
          -  Asthma that is uncontrolled, as defined by a score on the Asthma Control Test of 19 or&#xD;
             lower, or a worsening of asthma in the past year that led to an asthma&#xD;
             hospitalization, Emergency Department visit, or 3 days of oral corticosteroids&#xD;
&#xD;
          -  Severity of asthma that, in the opinion of the subject's asthma care specialist,&#xD;
             requires dupilumab for control&#xD;
&#xD;
          -  For women of childbearing age: agree to use birth control or remain abstinent during&#xD;
             the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with diagnosis of other chronic lung diseases (e.g. Chronic obstructive&#xD;
             pulmonary disease (COPD), idiopathic pulmonary fibrosis, Churg-Strauss syndrome,&#xD;
             Allergic bronchopulmonary aspergillosis, etc.)&#xD;
&#xD;
          -  Current smoker or reported smoking within 1 month of the screening visit (tobacco or&#xD;
             any inhaled recreational product)&#xD;
&#xD;
          -  Greater than 10 total pack-year of cigarette smoking history&#xD;
&#xD;
          -  Treatment with oral corticosteroids for an asthma exacerbation 1 month prior to&#xD;
             screening or during the screening period&#xD;
&#xD;
          -  Use of any biologic therapy for asthma within the past 3 months&#xD;
&#xD;
          -  Respiratory or Gastrointestinal illness within 1 month prior to screening or during&#xD;
             the screening period&#xD;
&#xD;
          -  Treatment with antibiotics for acute infections within six weeks prior to screening or&#xD;
             during the screening period.&#xD;
&#xD;
          -  Pregnancy at enrollment or during the study&#xD;
&#xD;
          -  Known hypersensitivity to dupilumab or its excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Hadden</last_name>
    <phone>734-232-1387</phone>
    <email>mhadden@umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvonne Huang, MD</last_name>
    <phone>734-936-5010</phone>
    <email>yvjhuang@umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Hadden</last_name>
      <phone>734-232-1387</phone>
      <email>mhadden@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Yvonne Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Yvonne J Huang</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Inhaled corticosteroids</keyword>
  <keyword>Dupilumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

